263: Biogen's messy board, Laronde's data problem, & the downside of a boom
The Readout Loud
00:00
Laurent's EQRX Data Issue
Meg Urry: Investors have not cared to comment on what's happening with Laurent at this point. How much money they have left in the bank is unknown, she says. The company now says that their ambition is to launch a clinical trial within the next two years with new drug candidates.
Transcript
Play full episode
